Guidelines for establishing a maternal serum alpha-fetoprotein screening program

F. H. Wians, Gary Hankins, E. R. Yeomans, T. L. Hammond, D. M. Strickland

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

MSAFP screening is an accepted component of the prenatal evaluation of all obstetric patients. Several aspects of MSAFP screening are controversial, such as cost-effectiveness, given the low incidence (1-2/1,000 gravidas) of fetal NTDs in the general obstetrical population; weight correction of MoM values; use of an abnormal low MSAFP cutoff to investigate Down syndrome; and reporting of risk data for open NTDs, VWDs, and Down syndrome. Nevertheless, MSAFP testing is a standard of care, both in the civilian and military medical communities. Therefore, the critical decision facing military medical treatment facilities is not whether to offer MSAFP testing, but, rather, how will results for this test be provided? The options available include in-house testing and the significantly more expensive ship-out testing to a fee-for-service reference laboratory. We suggest that MSAFP testing can be cost-effectively and reliably performed in-house by military medical treatment facilities, provided that appropriate resources are available and the guidelines indicated above are adhered to for ensuring the accuracy and reproducibility of MSAFP and AFAFP test results.

Original languageEnglish (US)
Pages (from-to)468-472
Number of pages5
JournalMilitary Medicine
Volume155
Issue number10
StatePublished - 1990
Externally publishedYes

Fingerprint

alpha-Fetoproteins
Down Syndrome
Mothers
Guidelines
Fee-for-Service Plans
Ships
Standard of Care
Serum
Obstetrics
Cost-Benefit Analysis
Research Design
Weights and Measures
Costs and Cost Analysis
Incidence
Therapeutics
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Wians, F. H., Hankins, G., Yeomans, E. R., Hammond, T. L., & Strickland, D. M. (1990). Guidelines for establishing a maternal serum alpha-fetoprotein screening program. Military Medicine, 155(10), 468-472.

Guidelines for establishing a maternal serum alpha-fetoprotein screening program. / Wians, F. H.; Hankins, Gary; Yeomans, E. R.; Hammond, T. L.; Strickland, D. M.

In: Military Medicine, Vol. 155, No. 10, 1990, p. 468-472.

Research output: Contribution to journalArticle

Wians, FH, Hankins, G, Yeomans, ER, Hammond, TL & Strickland, DM 1990, 'Guidelines for establishing a maternal serum alpha-fetoprotein screening program', Military Medicine, vol. 155, no. 10, pp. 468-472.
Wians FH, Hankins G, Yeomans ER, Hammond TL, Strickland DM. Guidelines for establishing a maternal serum alpha-fetoprotein screening program. Military Medicine. 1990;155(10):468-472.
Wians, F. H. ; Hankins, Gary ; Yeomans, E. R. ; Hammond, T. L. ; Strickland, D. M. / Guidelines for establishing a maternal serum alpha-fetoprotein screening program. In: Military Medicine. 1990 ; Vol. 155, No. 10. pp. 468-472.
@article{e73b44bb54eb495caa4c8c8c80cb3cdf,
title = "Guidelines for establishing a maternal serum alpha-fetoprotein screening program",
abstract = "MSAFP screening is an accepted component of the prenatal evaluation of all obstetric patients. Several aspects of MSAFP screening are controversial, such as cost-effectiveness, given the low incidence (1-2/1,000 gravidas) of fetal NTDs in the general obstetrical population; weight correction of MoM values; use of an abnormal low MSAFP cutoff to investigate Down syndrome; and reporting of risk data for open NTDs, VWDs, and Down syndrome. Nevertheless, MSAFP testing is a standard of care, both in the civilian and military medical communities. Therefore, the critical decision facing military medical treatment facilities is not whether to offer MSAFP testing, but, rather, how will results for this test be provided? The options available include in-house testing and the significantly more expensive ship-out testing to a fee-for-service reference laboratory. We suggest that MSAFP testing can be cost-effectively and reliably performed in-house by military medical treatment facilities, provided that appropriate resources are available and the guidelines indicated above are adhered to for ensuring the accuracy and reproducibility of MSAFP and AFAFP test results.",
author = "Wians, {F. H.} and Gary Hankins and Yeomans, {E. R.} and Hammond, {T. L.} and Strickland, {D. M.}",
year = "1990",
language = "English (US)",
volume = "155",
pages = "468--472",
journal = "Military Medicine",
issn = "0026-4075",
publisher = "Association of Military Surgeons of the US",
number = "10",

}

TY - JOUR

T1 - Guidelines for establishing a maternal serum alpha-fetoprotein screening program

AU - Wians, F. H.

AU - Hankins, Gary

AU - Yeomans, E. R.

AU - Hammond, T. L.

AU - Strickland, D. M.

PY - 1990

Y1 - 1990

N2 - MSAFP screening is an accepted component of the prenatal evaluation of all obstetric patients. Several aspects of MSAFP screening are controversial, such as cost-effectiveness, given the low incidence (1-2/1,000 gravidas) of fetal NTDs in the general obstetrical population; weight correction of MoM values; use of an abnormal low MSAFP cutoff to investigate Down syndrome; and reporting of risk data for open NTDs, VWDs, and Down syndrome. Nevertheless, MSAFP testing is a standard of care, both in the civilian and military medical communities. Therefore, the critical decision facing military medical treatment facilities is not whether to offer MSAFP testing, but, rather, how will results for this test be provided? The options available include in-house testing and the significantly more expensive ship-out testing to a fee-for-service reference laboratory. We suggest that MSAFP testing can be cost-effectively and reliably performed in-house by military medical treatment facilities, provided that appropriate resources are available and the guidelines indicated above are adhered to for ensuring the accuracy and reproducibility of MSAFP and AFAFP test results.

AB - MSAFP screening is an accepted component of the prenatal evaluation of all obstetric patients. Several aspects of MSAFP screening are controversial, such as cost-effectiveness, given the low incidence (1-2/1,000 gravidas) of fetal NTDs in the general obstetrical population; weight correction of MoM values; use of an abnormal low MSAFP cutoff to investigate Down syndrome; and reporting of risk data for open NTDs, VWDs, and Down syndrome. Nevertheless, MSAFP testing is a standard of care, both in the civilian and military medical communities. Therefore, the critical decision facing military medical treatment facilities is not whether to offer MSAFP testing, but, rather, how will results for this test be provided? The options available include in-house testing and the significantly more expensive ship-out testing to a fee-for-service reference laboratory. We suggest that MSAFP testing can be cost-effectively and reliably performed in-house by military medical treatment facilities, provided that appropriate resources are available and the guidelines indicated above are adhered to for ensuring the accuracy and reproducibility of MSAFP and AFAFP test results.

UR - http://www.scopus.com/inward/record.url?scp=0025114878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025114878&partnerID=8YFLogxK

M3 - Article

C2 - 1700337

AN - SCOPUS:0025114878

VL - 155

SP - 468

EP - 472

JO - Military Medicine

JF - Military Medicine

SN - 0026-4075

IS - 10

ER -